Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Jonathan Kay, MD

    Jonathan Kay, MD

    Director of Clinical Research 
    Rheumatology Division 
    Professor of Medicine 
    University of Massachusetts Medical School 
    Worcester, MA 


    Related Videos

    How do biosimilars differ from biomimics? Video

    How do biosimilars differ from biomimics?

    How do biosimilars differ from biomimics?

    What are the current price differences between the originator product such as brand/originator versions for infliximab versus the biosimilar? Does it vary from country to country? Video

    What are the current price differences between the originator product such as brand/originator versions for infliximab versus the biosimilar? Does it vary from country to country?

    What are the current price differences between the originator product such as brand/originator versions for infliximab versus the biosimilar? Does it vary from country to country? From Europe to the U.S.?

    What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR- SWITCH study; and what are the implications for clinical practice? Video

    What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR- SWITCH study; and what are the implications for clinical practice?

    What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR- SWITCH study; and what are the implications for clinical practice?

    Can you discuss study design, rationale, results, and clinical implications of the most recent clinical evidence focused on the safety, immunogenicity, and efficacy of approved biosimilar therapies for RA? Video

    Can you discuss study design, rationale, results, and clinical implications of the most recent clinical evidence focused on the safety, immunogenicity, and efficacy of approved biosimilar therapies for RA?

    Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence—i.e. clinical trial—focused on the safety, immunogenicity, and efficacy of approved biosimilar therapies for ...

    Since the efficacy of biosimilars is typically studied for a single indication, why are approvals of such biosimilars as INFLIXIMAB-DYYB extended to other diseases in which the biosimilar was not tested directly against the reference Video

    Since the efficacy of biosimilars is typically studied for a single indication, why are approvals of such biosimilars as INFLIXIMAB-DYYB extended to other diseases in which the biosimilar was not tested directly against the reference

    Since the clinical efficacy of biosimilars is typically studied for a single indication, why then are approvals of such biosimilars as INFLIXIMAB-DYYB, for example, extended to other disease states in which the biosimilar was not tested ...

    What steps in the development of an anti-TNF biosimilar such as infliximab ensure the likelihood that the reference product and biosimilar produce similar clinical effects? Video

    What steps in the development of an anti-TNF biosimilar such as infliximab ensure the likelihood that the reference product and biosimilar produce similar clinical effects?

    What are the analytical steps in the development process of an anti-TNF biosimilar such as infliximab that will ensure the likelihood that the reference product and biosimilar produce similar clinical effects in patients?

    Even though biopharmaceuticals and biosimilars are made in different manufacturing contexts, do we have data to confirm that such differences are clinically insignificant in the case of biosimilars for infliximab used in RA? Video

    Even though biopharmaceuticals and biosimilars are made in different manufacturing contexts, do we have data to confirm that such differences are clinically insignificant in the case of biosimilars for infliximab used in RA?

    Even though biopharmaceuticals and biosimilars are made in different manufacturing contexts—as opposed to small compound generic drugs—do we have enough data to confirm that such differences are clinically insignificant in the case of, ...

    What are the implications of using anti-TNF biosimilars for clinical practice in RA? For cost savings? What have we learned about biosimilars for infliximab in the setting of RA? Video

    What are the implications of using anti-TNF biosimilars for clinical practice in RA? For cost savings? What have we learned about biosimilars for infliximab in the setting of RA?

    What are the implications of using anti-TNF biosimilars for clinical practice in RA? For cost savings? What have we learned from the studies about biosimilars for infliximab in the setting of RA?

    Can you discuss each phase -- manufacturing, efficacy and safety testing, PK/PD evaluation, clinical outcomes evaluation -- in the approach to regulatory approval of biosimilars? Video

    Can you discuss each phase -- manufacturing, efficacy and safety testing, PK/PD evaluation, clinical outcomes evaluation -- in the approach to regulatory approval of biosimilars?

    Can you discuss the clinical and pharmacologic implications of each phase — manufacturing, efficacy and safety testing, PK/PD evaluation, clinical outcomes evaluation — in the stepwise approach to regulatory approval of biosimilar therapies, ...

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED